LaShawn Glasgow
Dados Biográficos
| ID | 6076115 |
|---|---|
| NOME | LaShawn Glasgow |
| PRENOMES | LaShawn |
| SOBRENOME | Glasgow |
| ASSINATURA | GLASGOW L |
| AFILIAÇÕES | Avik Chatterjee is with Boston University School of Medicine and Boston Medical Center, Boston, MA. LaShawn Glasgow and Emmanuel A. Oga are with RTI International, Research Triangle Park, NC. Mackenzie Bullard is with Boston University School of Medicine. At the time of study, Mariah Sabir was with Boston University School of Medicine. Greer Hamilton, Deborah Chassler, and Linda Sprague Martinez are with the Boston University School of Social Work. Danelle Stevens-Watkins is with the University of... |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 4 |
| TOTAL DE CITAÇÕES | 1 |
| TOTAL COMO AUTOR | 4 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2020 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2025 |
| ÍNDICE H | 1 |
Overdose education and naloxone distribution in jails
BACKGROUND: Opioid-related overdose is the leading cause of mortality among individuals recently released from incarceration in the U.S. Naloxone is an FDA-approved opioid antagonist medication designed to rapidly reverse opioid overdose. Despite evidence of its acceptability and effectiveness at reducing the risk of opioid overdose death after release from incarceration, only an estimated 25% of US jails provide naloxone upon release. This study…
Key insights on multisector community partnerships from real-world efforts to address social determinants of health
Placing Racial Equity at the Center of Substance Use Research
Key Insights on Participation Measurement from Real-world Health Care Interventions
Key Insights on Participation Measurement from Real-world Health Care Interventions
Placing Racial Equity at the Center of Substance Use Research
Key insights on multisector community partnerships from real-world efforts to address social determinants of health
Overdose education and naloxone distribution in jails
BACKGROUND: Opioid-related overdose is the leading cause of mortality among individuals recently released from incarceration in the U.S. Naloxone is an FDA-approved opioid antagonist medication designed to rapidly reverse opioid overdose. Despite evidence of its acceptability and effectiveness at reducing the risk of opioid overdose death after release from incarceration, only an estimated 25% of US jails provide naloxone upon release. This study…
Medicine (3 obras) · Nursing (3 obras) · Psychology (3 obras) · Public health (3 obras) · Economic growth (2 obras) · Economics (2 obras) · Equity (law) (2 obras) · Health equity (2 obras) · Opioid Use Disorder Treatment (2 obras) · Political science (2 obras)